Literature DB >> 16154847

Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.

Miguel A Sanz1, Pierre Fenaux, Francesco Lo Coco.   

Abstract

Recent studies have demonstrated the beneficial effects of arsenic trioxide (ATO) in the treatment of relapsed acute promyelocytic leukemia (APL). The aim of this review is to discuss the role of ATO in the management of APL. Based on the available clinical evidence, a tentative algorithm is proposed for the treatment of patients who relapse after or are refractory to all trans-retinoic acid-based therapy. Other opportunities for the use of ATO in front-line treatment of APL are also discussed, especially its potential use in patients at high risk of relapse and in those with contraindications to chemotherapy or in whom the amount of chemotherapy should be reduced.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16154847

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  12 in total

1.  Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.

Authors:  E Lengfelder; F Lo-Coco; L Ades; P Montesinos; D Grimwade; B Kishore; S M Ramadan; M Pagoni; M Breccia; A J G Huerta; A M Nloga; J D González-Sanmiguel; A Schmidt; J-F Lambert; S Lehmann; E Di Bona; B Cassinat; W-K Hofmann; D Görlich; M-C Sauerland; P Fenaux; M Sanz
Journal:  Leukemia       Date:  2015-01-28       Impact factor: 11.528

2.  A novel arsenate reductase from the arsenic hyperaccumulating fern Pteris vittata.

Authors:  Danielle R Ellis; Luke Gumaelius; Emily Indriolo; Ingrid J Pickering; Jo Ann Banks; David E Salt
Journal:  Plant Physiol       Date:  2006-06-09       Impact factor: 8.340

3.  Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.

Authors:  Hui Zhao; Wei Guo; Changliang Peng; Tao Ji; Xinchang Lu
Journal:  Mol Biol Rep       Date:  2009-08-22       Impact factor: 2.316

4.  History of acute promyelocytic leukemia: a tale of endless revolution.

Authors:  Francesco Lo-Coco; Laura Cicconi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-21       Impact factor: 2.576

5.  Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.

Authors:  Ezhilarasi Chendamarai; Saravanan Ganesan; Ansu Abu Alex; Vandana Kamath; Sukesh C Nair; Arun Jose Nellickal; Nancy Beryl Janet; Vivi Srivastava; Kavitha M Lakshmi; Auro Viswabandya; Aby Abraham; Mohammed Aiyaz; Nandita Mullapudi; Raja Mugasimangalam; Rose Ann Padua; Christine Chomienne; Mammen Chandy; Alok Srivastava; Biju George; Poonkuzhali Balasubramanian; Vikram Mathews
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

6.  Arsenic sulfide, the main component of realgar, a traditional Chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo.

Authors:  Lian Zhang; Wei Tian; Sungkyoung Kim; Wenping Ding; Yingying Tong; Siyu Chen
Journal:  Drug Des Devel Ther       Date:  2014-12-16       Impact factor: 4.162

7.  Study of baseline echocardiography and treatment endpoint in patients with acute lymphoblastic leukemia.

Authors:  Gholamreza Bahoush; Semira Mehralizadeh; Neda Tavakoli; Marzieh Nojoomi
Journal:  J Family Med Prim Care       Date:  2020-02-28

8.  Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells.

Authors:  Jacopo Albanesi; Nelida Ines Noguera; Cristina Banella; Tommaso Colangelo; Elisabetta De Marinis; Stefano Leone; Orazio Palumbo; Maria Teresa Voso; Paolo Ascenzi; Clara Nervi; Fabrizio Bianchi; Alessandra di Masi
Journal:  Cells       Date:  2020-11-05       Impact factor: 6.600

9.  Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Authors:  Haibo Sun; De-Chen Lin; Xiao Guo; Behzad Kharabi Masouleh; Sigal Gery; Qi Cao; Serhan Alkan; Takayuki Ikezoe; Chie Akiba; Ronald Paquette; Wenwen Chien; Carsten Müller-Tidow; Yang Jing; Konstantin Agelopoulos; Markus Müschen; H Phillip Koeffler
Journal:  Oncotarget       Date:  2016-04-05

10.  2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia.

Authors:  Ying Lu; Jin-Song Yan; Li Xia; Kang Qin; Qian-Qian Yin; Hong-Tao Xu; Meng-Qing Gao; Xiao-Ning Qu; Yu-Ting Sun; Guo-Qiang Chen
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.